{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:04:23Z","timestamp":1792839863356,"version":"4.5.0"},"reference-count":172,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":504,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13311-022-01206-x","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T11:08:49Z","timestamp":1646910529000},"page":"808-822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD"],"prefix":"10.1016","volume":"19","author":[{"given":"Vyanka","family":"Redenbaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-2910","authenticated-orcid":false,"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9451","key":"10.1007\/s13311-022-01206-x_bib1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1007\/s13311-022-01206-x_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01206-x_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.045","article-title":"Neuromyelitis optica: effect of gender","volume":"286","author":"Wingerchuk","year":"2009","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000284600.80782.d5","article-title":"Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders","volume":"70","author":"Banwell","year":"2008","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-022-01206-x_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cen3.12107","article-title":"Evaluation of aquaporin-4 antibody assays","volume":"5","author":"Waters","year":"2014","journal-title":"Clin Exp Neurol."},{"key":"10.1007\/s13311-022-01206-x_bib12","doi-asserted-by":"crossref","unstructured":"Fryer J, Lennon V, Pittock S, Jenkins S, Fallier-Becker P, Clardy S, et al. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm. 2014;1(1).","DOI":"10.1212\/NXI.0000000000000011"},{"key":"10.1007\/s13311-022-01206-x_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 Antibody assay sensitivity comparison in the era of the 2015 Diagnostic Criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front Neurol"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1007\/s13311-022-01206-x_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00415-010-5780-4","article-title":"Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients","volume":"258","author":"Akman-Demir","year":"2011","journal-title":"J Neurol"},{"issue":"14","key":"10.1007\/s13311-022-01206-x_bib17","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat Med"},{"issue":"8","key":"10.1007\/s13311-022-01206-x_bib19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/jamaneurol.2018.1055","article-title":"Anti-myelin oligodendrocyte glycoprotein antibody-associated central nervous system demyelination-a novel disease entity?","volume":"75","author":"Weber","year":"2018","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib20","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awx292","article-title":"MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?","volume":"140","author":"de Seze","year":"2017","journal-title":"Brain"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib21","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1001\/jamaneurol.2020.2743","article-title":"Application of 2015 seronegative neuromyelitis optica spectrum disorder diagnostic criteria for patients with myelin oligodendrocyte glycoprotein IgG-associated disorders","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1007\/s13311-022-01206-x_bib22","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib23","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jamaneurol.2020.3115","article-title":"Long-term outcomes in patients with myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder","volume":"77","author":"Lopez-Chiriboga","year":"2020","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib24","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical Features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01206-x_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult Scler"},{"issue":"10","key":"10.1007\/s13311-022-01206-x_bib28","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire","volume":"91","author":"O'Connell","year":"2020","journal-title":"UK J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1007\/s13311-022-01206-x_bib29","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1177\/1352458520948213","article-title":"Comparison of MOG and AQP4 antibody seroprevalence in Korean adults with inflammatory demyelinating CNS diseases","volume":"27","author":"Hyun","year":"2021","journal-title":"Mult Scler"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1007\/s13311-022-01206-x_bib32","doi-asserted-by":"crossref","unstructured":"Sechi E, Buciuc M, Pittock SJ, Chen JJ, Fryer JP, Jenkins SM, et al. Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol. 2021.","DOI":"10.1001\/jamaneurol.2021.0912"},{"key":"10.1007\/s13311-022-01206-x_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-0716-1948-3_3","article-title":"Sample preparation and fixation for histology and pathology","volume":"2422","author":"Sampedro-Carrillo","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"11","key":"10.1007\/s13311-022-01206-x_bib34","doi-asserted-by":"crossref","first-page":"e1250","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib36","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib37","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01206-x_bib38","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1007\/s13311-022-01206-x_bib39","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-022-01206-x_bib40","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","article-title":"Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2","volume":"205","author":"Hinson","year":"2008","journal-title":"J Exp Med"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib41","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/glia.22635","article-title":"Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures","volume":"62","author":"Howe","year":"2014","journal-title":"Glia"},{"issue":"Pt 2","key":"10.1007\/s13311-022-01206-x_bib42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"issue":"Pt 7","key":"10.1007\/s13311-022-01206-x_bib43","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"8","key":"10.1007\/s13311-022-01206-x_bib44","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","article-title":"Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment","volume":"181","author":"Vincent","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/ni.1794","article-title":"Checkpoints in lymphocyte development and autoimmune disease","volume":"11","author":"von Boehmer","year":"2010","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1007\/s13311-022-01206-x_bib46","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/brain\/awz106","article-title":"Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production","volume":"142","author":"Cotzomi","year":"2019","journal-title":"Brain"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib47","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10875-012-9709-9","article-title":"Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse","volume":"32","author":"Wang","year":"2012","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1352458512454771","article-title":"Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis","volume":"19","author":"Quan","year":"2013","journal-title":"Mult Scler"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib50","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-022-01206-x_bib51","doi-asserted-by":"crossref","unstructured":"Chihara N, Aranami T, Oki S, Matsuoka T, Nakamura M, Kishida H, et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One. 2013;8(12):e83036.","DOI":"10.1371\/journal.pone.0083036"},{"key":"10.1007\/s13311-022-01206-x_bib52","doi-asserted-by":"crossref","unstructured":"Bennett JL, O'Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e104.","DOI":"10.1212\/NXI.0000000000000104"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01206-x_bib54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12974-015-0240-9","article-title":"The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations","volume":"12","author":"Kowarik","year":"2015","journal-title":"J Neuroinflammation"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41582-020-0381-z","article-title":"The B cell immunobiology that underlies CNS autoantibody-mediated diseases","volume":"16","author":"Sun","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib56","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms17030273","article-title":"The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives","volume":"17","author":"Jasiak-Zatonska","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1007\/s13311-022-01206-x_bib57","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1007\/s13311-022-01206-x_bib58","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: a review in neuromyelitis optica spectrum disorder","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"issue":"1\u20132","key":"10.1007\/s13311-022-01206-x_bib59","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jneuroim.2012.09.002","article-title":"Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica","volume":"254","author":"Kuroda","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-022-01206-x_bib60","doi-asserted-by":"crossref","unstructured":"Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, et al. Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One. 2013;8(4):e61835.","DOI":"10.1371\/journal.pone.0061835"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib61","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"10.1007\/s13311-022-01206-x_bib62","doi-asserted-by":"crossref","unstructured":"Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5).","DOI":"10.1212\/NXI.0000000000000841"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib63","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1159\/000339302","article-title":"Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica","volume":"19","author":"Wang","year":"2012","journal-title":"NeuroImmunoModulation"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib64","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","article-title":"Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients","volume":"120","author":"I\u00e7\u00f6z","year":"2010","journal-title":"Int J Neurosci"},{"key":"10.1007\/s13311-022-01206-x_bib65","doi-asserted-by":"crossref","unstructured":"Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4(1):e311.","DOI":"10.1212\/NXI.0000000000000311"},{"issue":"4","key":"10.1007\/s13311-022-01206-x_bib66","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awy010","article-title":"Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica","volume":"141","author":"Wilson","year":"2018","journal-title":"Brain"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib67","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3109\/00207454.2016.1163550","article-title":"Th17 cells in neuromyelitis optica spectrum disorder: a review","volume":"126","author":"Lin","year":"2016","journal-title":"Int J Neurosci"},{"issue":"7","key":"10.1007\/s13311-022-01206-x_bib68","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1007\/s13311-022-01206-x_bib69","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.3389\/fimmu.2019.02686","article-title":"The balance in T follicular helper cell subsets is altered in neuromyelitis optica spectrum disorder patients and restored by rituximab","volume":"10","author":"Nicolas","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1007\/s13311-022-01206-x_bib70","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.4049\/jimmunol.175.6.3463","article-title":"Directing transition from innate to acquired immunity: defining a role for IL-6","volume":"175","author":"Jones","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"10.1007\/s13311-022-01206-x_bib71","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01206-x_bib72","unstructured":"Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke K-D, Hellwig K, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurology(R) neuroimmunology & neuroinflammation. 2018;5(6):e504-e."},{"issue":"4","key":"10.1007\/s13311-022-01206-x_bib73","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","article-title":"Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro","volume":"7","author":"Wang","year":"2004","journal-title":"Angiogenesis"},{"issue":"7","key":"10.1007\/s13311-022-01206-x_bib74","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1172\/JCI60842","article-title":"Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease","volume":"122","author":"Argaw","year":"2012","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1007\/s13311-022-01206-x_bib75","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/cen3.12239","article-title":"Bevacizumab is safe in acute relapses of neuromyelitis optica","volume":"6","author":"Mealy","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"issue":"13","key":"10.1007\/s13311-022-01206-x_bib76","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1212\/WNL.0000000000012599","article-title":"CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies","volume":"97","author":"Zhao-Fleming","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1007\/s13311-022-01206-x_bib78","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib79","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00415-015-7925-y","article-title":"Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series","volume":"263","author":"Azzopardi","year":"2016","journal-title":"J Neurol"},{"key":"10.1007\/s13311-022-01206-x_bib81","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","article-title":"Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis","volume":"35","author":"Huang","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1007\/s13311-022-01206-x_bib82","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01206-x_bib83","unstructured":"Neuromyelitis optica: new therapies offer hope: Mayo Clinic Medical Professionals\/ Neurology and neurosurgery; 6\/19\/2021 [Available from: https:\/\/www.mayoclinic.org\/medical-professionals\/neurology-neurosurgery\/news\/neuromyelitis-optica-new-therapies-offer-hope\/mac-20515747."},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib84","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.msard.2013.10.003","article-title":"Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"3","author":"Graves","year":"2014","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1007\/s13311-022-01206-x_bib85","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B cells as therapeutic targets in autoimmune neurological disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib86","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B cell responses: cell interaction dynamics and decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"Cell"},{"key":"10.1007\/s13311-022-01206-x_bib87","doi-asserted-by":"crossref","unstructured":"M\u00f6ckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. 2021;20(2):102736.","DOI":"10.1016\/j.autrev.2020.102736"},{"issue":"6","key":"10.1007\/s13311-022-01206-x_bib88","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1186\/ar2076","article-title":"Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"8","author":"Vallerskog","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib89","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1007\/s13311-022-01206-x_bib90","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"issue":"15","key":"10.1007\/s13311-022-01206-x_bib92","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1007\/s13311-022-01206-x_bib93","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1007\/s13311-022-01206-x_bib94","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult Scler"},{"issue":"11","key":"10.1007\/s13311-022-01206-x_bib95","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib96","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol"},{"issue":"11","key":"10.1007\/s13311-022-01206-x_bib97","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1007\/s13311-022-01206-x_bib98","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib99","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01206-x_bib100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib101","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.14447","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and\/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial","volume":"176","author":"Sharman","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib102","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10616-011-9377-2","article-title":"Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity","volume":"64","author":"Konno","year":"2012","journal-title":"Cytotechnology"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib103","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2013.240","article-title":"Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion","volume":"28","author":"Le Garff-Tavernier","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1007\/s13311-022-01206-x_bib104","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s12264-020-00525-3","article-title":"Monoclonal antibody-based treatments for neuromyelitis optica spectrum disorders: from bench to bedside","volume":"36","author":"Zhu","year":"2020","journal-title":"Neurosci Bull"},{"key":"10.1007\/s13311-022-01206-x_bib105","doi-asserted-by":"crossref","unstructured":"Mealy MA, Levy M. A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 2019;98(25):e15944.","DOI":"10.1097\/MD.0000000000015944"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib106","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.4049\/jimmunol.1501843","article-title":"Distinctions among circulating antibody-secreting cell populations, including B-1 cells, in human adult peripheral blood","volume":"196","author":"Qu\u00e1ch","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Role of B cells in multiple sclerosis and related disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib108","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4161\/mabs.21338","article-title":"CD19 as an attractive target for antibody-based therapy","volume":"4","author":"Hammer","year":"2012","journal-title":"MAbs"},{"key":"10.1007\/s13311-022-01206-x_bib109","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"10206","key":"10.1007\/s13311-022-01206-x_bib110","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1007\/s13311-022-01206-x_bib111","doi-asserted-by":"crossref","unstructured":"Jitprapaikulsan J, Fryer JP, Majed M, Smith CY, Jenkins SM, Cabre P, et al. Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurol Neuroimmunol Neuroinflamm. 2020;7(4).","DOI":"10.1212\/NXI.0000000000000727"},{"key":"10.1007\/s13311-022-01206-x_bib112","doi-asserted-by":"crossref","unstructured":"Akaishi T, Takahashi T, Nakashima I, Abe M, Ishii T, Aoki M, et al. Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD). J Neurol Sci. 2020;410:116671.","DOI":"10.1016\/j.jns.2020.116671"},{"key":"10.1007\/s13311-022-01206-x_bib113","doi-asserted-by":"crossref","unstructured":"Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u2a7e4 years in the N-MOmentum trial. Mult Scler. 2021:13524585211047223.","DOI":"10.1177\/13524585211047223"},{"key":"10.1007\/s13311-022-01206-x_bib114","doi-asserted-by":"crossref","unstructured":"Shi B, Zhao M, Qiao L, Huang F, Zhou S, Wei Y, et al. Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2021;54:103143.","DOI":"10.1016\/j.msard.2021.103143"},{"key":"10.1007\/s13311-022-01206-x_bib115","doi-asserted-by":"crossref","unstructured":"Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, et al. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler. 2021:1352458521988926.","DOI":"10.1177\/1352458521988926"},{"key":"10.1007\/s13311-022-01206-x_bib116","doi-asserted-by":"crossref","unstructured":"Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, et al. Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2021;8(3).","DOI":"10.1212\/NXI.0000000000000978"},{"key":"10.1007\/s13311-022-01206-x_bib117","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"10.1007\/s13311-022-01206-x_bib118","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.intimp.2017.09.005","article-title":"Immunoglobulin replacement therapy in primary and secondary antibody deficiency: the correct clinical approach","volume":"52","author":"Pecoraro","year":"2017","journal-title":"Int Immunopharmacol"},{"issue":"13","key":"10.1007\/s13311-022-01206-x_bib119","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib120","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib121","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib122","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrrheum.2017.198","article-title":"Autoimmunity and primary immunodeficiency: two sides of the same coin?","volume":"14","author":"Schmidt","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib123","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00115-019-0760-0","article-title":"Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis: current status and recommendations in Germany","volume":"90","author":"Bittner","year":"2019","journal-title":"Nervenarzt"},{"key":"10.1007\/s13311-022-01206-x_bib124","unstructured":"Rheumatology ACo. Medication guide: rituximab [updated February 2020. Available from: https:\/\/www.rheumatology.org\/Learning-Center\/Medication-Guides\/Medication-Guide-Rituximab-Rituxan."},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib125","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s10067-015-3099-3","article-title":"Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom","volume":"34","author":"Nisar","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib126","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/acn3.491","article-title":"Infectious risk stratification in multiple sclerosis patients receiving immunotherapy","volume":"4","author":"Graf","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1007\/s13311-022-01206-x_bib127","unstructured":"Ask Mayo Expert, NMOSD medication monitoring guidelines [updated 2\/24\/2021. Available from: https:\/\/askmayoexpert.mayoclinic.org\/topic\/clinical-answers\/gnt-20508358\/sec-20508395#jumplinkin3."},{"key":"10.1007\/s13311-022-01206-x_bib128","doi-asserted-by":"crossref","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169.","DOI":"10.1001\/jamanetworkopen.2018.4169"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract Neurol"},{"issue":"15","key":"10.1007\/s13311-022-01206-x_bib130","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib131","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib132","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/14397595.2013.861333","article-title":"Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report","volume":"26","author":"Komai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1007\/s13311-022-01206-x_bib133","doi-asserted-by":"crossref","unstructured":"Rigal J, Pugnet G, Ciron J, L\u00e9pine Z, Biotti D. Off-label use of tocilizumab in neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases: a case-series. Mult Scler Relat Disord. 2020;46:102483.","DOI":"10.1016\/j.msard.2020.102483"},{"issue":"7","key":"10.1007\/s13311-022-01206-x_bib134","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib135","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib136","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib137","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/1060028020976669","article-title":"Satralizumab for the treatment of neuromyelitis optica spectrum disorders","volume":"55","author":"Gao","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"14","key":"10.1007\/s13311-022-01206-x_bib138","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","article-title":"Satralizumab: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"issue":"22","key":"10.1007\/s13311-022-01206-x_bib139","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01206-x_bib141","doi-asserted-by":"crossref","unstructured":"Duan T, Tradtrantip L, Phuan PW, Bennett JL, Verkman AS. Affinity-matured \u2018aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology. 2020;162:107827.","DOI":"10.1016\/j.neuropharm.2019.107827"},{"issue":"12","key":"10.1007\/s13311-022-01206-x_bib142","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14728222.2017.1398236","article-title":"The aquaporin-4 water channel as a potential drug target in neurological disorders","volume":"21","author":"Verkman","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib143","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1096\/fj.11-201608","article-title":"Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica","volume":"26","author":"Tradtrantip","year":"2012","journal-title":"Faseb j"},{"issue":"6","key":"10.1007\/s13311-022-01206-x_bib144","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01206-x_bib145","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib146","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/practneurol-2017-001787","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations","volume":"19","author":"Jury\u0144czyk","year":"2019","journal-title":"Pract Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J Neurochem"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib148","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1007\/s13311-022-01206-x_bib149","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.4049\/jimmunol.1801295","article-title":"Autoantibodies against neurologic antigens in nonneurologic autoimmunity","volume":"202","author":"Stathopoulos","year":"2019","journal-title":"J Immunol"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib150","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"issue":"21","key":"10.1007\/s13311-022-01206-x_bib151","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01206-x_bib152","doi-asserted-by":"crossref","unstructured":"Lehmann-Horn K, Wang SZ, Sagan SA, Zamvil SS, von B\u00fcdingen HC. B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue. JCI Insight. 2016;1(20):e87234.","DOI":"10.1172\/jci.insight.87234"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib153","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1212\/WNL.0000000000012177","article-title":"Intrathecal production of MOG-IgG: highlighting the need for CSF testing in clinical practice","volume":"97","author":"Hacohen","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1007\/s13311-022-01206-x_bib154","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1212\/WNL.0000000000012175","article-title":"Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder","volume":"97","author":"Akaishi","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"10.1007\/s13311-022-01206-x_bib155","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/brain\/awab105","article-title":"Features of MOG required for recognition by patients with MOG antibody-associated disorders","volume":"144","author":"Macrini","year":"2021","journal-title":"Brain"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib156","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"H\u00f6ftberger","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1007\/s13311-022-01206-x_bib157","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"issue":"3","key":"10.1007\/s13311-022-01206-x_bib158","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/WCO.0000000000000828","article-title":"Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics","volume":"33","author":"Fujihara","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"10.1007\/s13311-022-01206-x_bib159","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI lesion evolution in different central nervous system demyelinating disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"key":"10.1007\/s13311-022-01206-x_bib160","doi-asserted-by":"crossref","unstructured":"Li X, Wang L, Zhou L, ZhangBao J, Miao MZ, Lu C, et al. The imbalance between regulatory and memory B cells accompanied by an increased number of circulating T-follicular helper cells in MOG-antibody-associated demyelination. Mult Scler Relat Disord. 2019;36:101397.","DOI":"10.1016\/j.msard.2019.101397"},{"issue":"6","key":"10.1007\/s13311-022-01206-x_bib161","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1212\/NXI.0000000000000625","article-title":"Identification of circulating MOG-specific B cells in patients with MOG antibodies","volume":"6","author":"Winklmeier","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1007\/s13311-022-01206-x_bib162","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-022-01206-x_bib163","doi-asserted-by":"crossref","unstructured":"Stiebel-Kalish H, Hellmann MA, Mimouni M, Paul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572.","DOI":"10.1212\/NXI.0000000000000572"},{"key":"10.1007\/s13311-022-01206-x_bib164","doi-asserted-by":"crossref","unstructured":"Bruijstens AL, Wendel EM, Lechner C, Bartels F, Finke C, Breu M, et al. E.U. paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020;29:41\u201353.","DOI":"10.1016\/j.ejpn.2020.10.005"},{"issue":"4","key":"10.1007\/s13311-022-01206-x_bib165","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib166","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1007\/s13311-022-01206-x_bib167","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01206-x_bib168","doi-asserted-by":"crossref","unstructured":"Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): a case-series and review. Mult Scler Relat Disord. 2021;48:102696.","DOI":"10.1016\/j.msard.2020.102696"},{"key":"10.1007\/s13311-022-01206-x_bib169","doi-asserted-by":"crossref","unstructured":"Zuercher AW, Spirig R, Baz Morelli A, Rowe T, K\u00e4sermann F. Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev. 2019;18(10):102366.","DOI":"10.1016\/j.autrev.2019.102366"},{"issue":"7","key":"10.1007\/s13311-022-01206-x_bib170","first-page":"1111","article-title":"Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"issue":"6","key":"10.1007\/s13311-022-01206-x_bib171","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"issue":"17","key":"10.1007\/s13311-022-01206-x_bib172","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01206-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01206-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01206-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:00:35Z","timestamp":1761807635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":172,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1878747923011042"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01206-x","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01206-x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}